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RESEARCH ARTICLE
Reassessment of areas with persistent
Lymphatic Filariasis nine years after cessation
of mass drug administration in Sri Lanka
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Sri Lanka was one of the first countries to initiate a lymphatic filariasis (LF) elimination pro-
gram based on WHO guidelines. The Anti-Filariasis Campaign provided 5 annual rounds of
mass drug administration (MDA) with diethylcarbamazine plus albendazole in all 8 endemic
districts from 2002–2006. Microfilaremia (Mf) prevalences have been consistently <1% in all
sentinel and spot-check sites since 2006, and all evaluation units passed school-based
transmission assessment surveys (TAS) in 2013. We previously reported results from com-
prehensive surveillance studies conducted in 2011–2013 that documented low-level persis-
tence of Wuchereria bancrofti in 19 high risk areas in 8 endemic districts. We now present
results from repeat surveys conducted 3 to 4 years later in 6 areas that had the strongest LF
signals in the prior study.
Methodology and principal findings
The surveys assessed prevalence of filarial antigenemia (CFA) and Mf in communities, CFA
and anti-filarial antibody in school children (ages 6–8), and filarial DNA in Culex mosquitoes
(molecular xenomonitoring, MX). Three study areas had significantly improved infection
parameters compared to the prior study, but three other areas had little change. MX was
more sensitive for detecting W. bancrofti persistence, and it was a better predictor than
other parameters. Adult males accounted for more than 80% of infections detected in the
study.
Conclusions
These results suggest that W. bancrofti transmission was near the break point in some of
the areas studied in 2011–13. LF is likely to decline to zero without further intervention in
these areas, while other areas may require further intervention. Long term surveillance may
be needed to verify W. bancrofti elimination in areas like Sri Lanka with efficient transmission
by Culex. Test and treat or other programs targeting adult males plus bed net promotion
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may be more effective than MDA for clearing remaining hotspots of transmission in Sri
Lanka.
Author summary
Lymphatic Filariasis (LF, also known as “elephantiasis”) is a disabling and deforming trop-
ical disease caused by parasitic worms that are transmitted by mosquitoes. The Sri Lankan
Anti-Filariasis Campaign provided 5 annual rounds of mass drug administration (MDA)
with diethylcarbamazine and albendazole between 2002 and 2006 in all endemic areas,
and this reduced infection prevalence to very low levels. Post-MDA surveillance con-
ducted by our group in 19 sentinel sites in 8 endemic districts in 2011–2013 revealed evi-
dence of persistent LF infection in all study sites. The present paper reports results of
repeat assessments conducted 3–4 years later in 6 areas with high signals in the prior
study. LF parameters were significantly improved in 3 areas where LF appears to be on a
glide path to elimination. However, LF infection parameters remained high in 3 areas,
and further work will probably be required to interrupt transmission in these areas.
Molecular xenomonitoring (to detect filarial DNA in mosquito vectors) was especially
sensitive for detecting persistent LF in Sri Lanka, and this may also be true in other areas
with Culex transmission. Our results suggest that test and treat or other programs target-
ing adult males plus expanded bed net use may be helpful for clearing up remaining LF
hotspots.
Introduction
Lymphatic filariasis (LF, caused by the filarial nematodes Wuchereria bancrofti, Brugia malayi,
and B. timori), is a major public-health problem in many tropical and subtropical countries.
The global program to eliminate Lymphatic Filariasis (GPELF) has made significant progress
by providing more than 6 billion treatments with antifilarial medications to more than 800
million people in some 60 countries between 2000 and 2015 [1]. This mass drug administra-
tion (MDA) program has cured millions of infections and prevented millions of new clinical
filariasis cases [1–3]. Countries with successful MDA programs are now looking for additional
guidance on stopping MDA and on post-MDA surveillance beyond WHO current guidelines
[1, 4, 5] that rely heavily on testing school aged children for filarial antigenemia as a means of
demonstrating that transmission of new infections has been interrupted. While such “trans-
mission assessment surveys” (TAS) can be a useful surveillance tool [4, 6], they have not been
adequately validated as an indicator for interruption of LF transmission at the evaluation unit
or country level. Indeed, prior studies by our group have shown that TAS was not sensitive for
detecting ongoing transmission of W. bancrofti in Sri Lanka [7], and this is likely to be true in
many other settings.
Lymphatic filariasis has been endemic in Sri Lanka for hundreds of years [8–11]. The coun-
try’s Anti Filariasis Campaign (AFC, established in 1947) implemented control activities over
many years that succeeded in reducing infection prevalence to low levels by 1999. After pro-
viding mass drug administration of diethylcarbamazine (DEC) for three years starting in 1999,
the AFC provided five annual rounds of MDA with diethylcarbamazine (DEC) plus albenda-
zole in all 8 endemic districts (implementation units, IU) between 2002 and 2006 [2, 12–14].
The AFC conducted post-MDA surveillance activities according to WHO guidelines, and all
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evaluation units in endemic districts easily passed TAS in 2013 [7]. Based on this and other
considerations, WHO recognized that Sri Lanka had eliminated LF as a public health problem
in 2016, but recommended that the country continue treatment interventions with high popu-
lation coverage and post-MDA surveillance in isolated foci with evidence of ongoing transmis-
sion [1, 15, 16].
We assessed the status of W. bancrofti in Sri Lanka with comprehensive post-MDA surveil-
lance in 19 Public Health Inspector areas that were considered to be at risk for persistent infec-
tion. Comprehensive surveillance comprised community surveys for circulating filarial
antigenemia (CFA) and microfilaremia (Mf), school surveys for CFA and antifilarial antibod-
ies, and systematic sampling of Culex quinquefasciatus for the presence of filarial DNA (molec-
ular xenomonitoring or MX) [7]. All 19 sentinel areas studied had evidence for persistent W.
bancrofti, but some areas had stronger signals than others. Based on results of that study, we
suggested revised endpoint targets for filariasis elimination programs in areas with Culex
transmission based on upper 95% confidence limits as follows: CFA <2%, antibody prevalence
in primary school children <5%, and filarial DNA prevalence in gravid, semigravid, or fed
Culex mosquitoes <1% [7]. In the present study we have repeated comprehensive surveillance
in 6 areas with the strongest signals for W. bancrofti persistence in 2011–2013 to determine
whether there was evidence for improvement or worsening of infection parameters 3 to 4
years after the prior study.
Methods
Ethical review and consent procedures
The study protocol was reviewed and approved by institutional review boards at Washington
University School of Medicine, University of Kelaniya and at the Ministry of Health in Sri
Lanka. Printed copies of participant information sheets (PIS) and written consent forms were
provided to participants (or to parents/guardians) in Sinhalese, Tamil and English. Written
consent was obtained from adults; participation of minors required written consent from at
least one parent or guardian plus assent by the child/minor.
Study sites
The study was performed in four Public Health Inspector (PHI) areas, one Public Health Field
Officer (PHFO) area and one in Colombo municipality area that had evidence of persistent LF
in a post-MDA surveillance study of 19 areas that was conducted in 2011–13 [7] (Fig 1). PHIs
are sub-district health administrative units with populations in the range of 10,000–30,000 that
are comprised of smaller units called Public Health Midwife (PHM) areas. The current study
was performed three to four years after the last evaluation. No treatment for filariasis was pro-
vided in this interval in 4 of these PHIs. One round of MDA with DEC plus albendazole was
provided in two of the PHIs (Unawatuna and Ambalangoda in Galle district) in 2014.
Blood collection
Field procedures were the same as those previously described [7]. Briefly, field teams for collec-
tion of demographic information and blood samples consisted of a medical officer, a Public
Health Inspector, a data entry operator, a phlebotomist, and one or two assistants. 1.5 mm x
2.0 mm, blue and 21 G x 1.8 mm pink single use contact-activated BD-microtainer lancets
(Fisher scientific, Pittsburgh, PA) were used for blood collection in community and school
surveys, respectively. Blood samples were collected during the day. Approximately 300 to
400 μl of blood was collected by finger prick from each study participant into an EDTA coated
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Fig 1. The map shows 8 filariasis endemic districts with approximate locations of 19 sentinel sites that were surveyed in 2011–2013 (blue and
red circles). Six areas in red circles in 5 districts were reexamined in 2015–2017 for this study. The inset map shows surveyed sentinel sites in Colombo
city and in the adjacent Colombo and Gampaha districts.
https://doi.org/10.1371/journal.pntd.0006066.g001
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blood collection vial (Fisher Scientific). Preprinted barcode labels were used to link samples to
participant records. Samples were transported to the central Antifilariasis Campaign (AFC)
laboratory in Colombo in coolers. Plasma was separated by centrifugation from blood samples
from school surveys and stored at -80 C for antibody testing.
Survey methods in communities and schools
Survey methods were the same as previously described [7]. Briefly, area maps, census informa-
tion (the number of houses and the number of households, number of schools, and the num-
ber of primary grade children) were obtained from census records, voter lists, and from school
principals and administrators [17]. Community surveys sampled approximately 500 partici-
pants (ages 10–70 years) in approximately 125 households per PHI/PHFO area (range 127–
172 HH). Most houses in the study area have 3 or 4 residents in this age range. Young children
tested in school surveys were too young for inclusion in the community surveys (no overlap).
Systematic sampling was used for household and mosquito sampling in each PHM within the
PHI area. The number of houses/households needed for each community survey (125) was
divided by number of PHMs in the PHI to get the number of houses to be sampled in each
PHM. That number was divided by 4 to get the number of houses to be sampled in each quad-
rant in each PHM area. The sampling interval for houses was calculated by dividing the num-
ber of houses that were to be sampled in that PHM quadrant. Households from all quadrants
in the PHM were enrolled. To maintain consistency in sampling and to obtain geographically
dispersed samples, only 4 subjects 10 years were enrolled per household with equal prefer-
ence for males and females. School surveys were performed in all schools that served the senti-
nel area. Finger prick blood was collected from primary grade school children (grades 1 and 2,
age 6–8) and community participants for antigen and antibody testing.
Filariasis testing for human subjects
Circulating filarial antigenemia (CFA) was detected in finger prick blood samples with a rapid
format card test (BinaxNOW Filariasis, Alere Inc., Scarborough, ME) according to the manu-
facturer’s instructions. Cards were read visually at 10 minutes. Antigen testing was performed
within 24 hr of blood collection.
IgG4 antibodies to recombinant filarial antigen Bm-14 in human plasma were detected by
microplate ELISA (Filariasis CELISA, Cellabs Pty Ltd, Brookvale, NSW, Australia) as previ-
ously described [18]. Plasma samples were tested in a single well per sample and all positive
and borderline tests with OD values >0.35 were retested on a different day to confirm their
positivity. Samples with OD values consistently >0.35 were considered to be positive for anti-
bodies to Bm14.
Persons with a positive filiarial antigen test had night blood testing to detect microfilaremia
(Mf) as previously described. Briefly, finger prick blood collected between 9 pm and 12 mid-
night was used to prepare three-line blood smears (60 μl total volume of blood tested) that
were dried, fixed, stained with Giemsa, and examined by microscopy for the presence of Mf.
Each stained slide was read by a single experienced microscopist who recorded the absence or
presence of Mf and Mf count.
Detection of filarial DNA in mosquitoes
Culex quinquefasciatus were collected with CDC gravid traps (Model 1712, John W. Hock
Company, Gainesville, FL) as previously described [7, 19]. Briefly, traps were placed outside
houses in shaded areas in all quadrants of each PHM to ensure proportional sampling from all
areas in each PHI. Trapped mosquitoes were sorted, dried at 950 C for 1 hr., and placed in
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tubes for later molecular testing. Four pools of twenty fed, gravid, or semigravid female Cx.
quinquefasciatus were tested from each of 50 trapping locations per PHI. Extraction of DNA
from mosquitoes and detection of W. bancrofti DNA by qPCR were performed at the AFC
central laboratory as previously described [20].
Data collection and data management
Demographic information was collected and entered into BLU phones (BLU products,
Miami, FL) using preloaded survey forms with LINKS data collection software https://www.
linkssystem.org. Cell phones are equipped with global positioning system (GPS) capability,
and GPS coordinates were captured at each surveyed house and mosquito trap location.
Enrollment forms collected information on age, gender, consumption of antifilarial medica-
tions during the 2000–2006 MDA, bed net use last night, and clinical signs of lymphedema (all
self-reported). Participant data and specimens were linked to laboratory test results with pre-
printed barcode labels. Deidentified, cleaned data were transferred into Microsoft Excel
(Microsoft Corp., Redmond, WA) for analysis.
Spatial analysis
Households included in population surveys and mosquito trapping sites were mapped using
ArcGIS 10.2.1 (ESRI, Redlands, CA).
Statistical methods
Chi-squared or Fisher’s exact tests were used to assess the significance of differences in filaria-
sis parameters (prevalence of surveyed persons positive for antigenemia and antibody and
percentages of mosquito pools that contained filarial DNA). Prevalence of filarial DNA in
mosquitoes (maximum likelihood and 95% CI) were estimated using Poolscreen 2.02 software
[21, 22]. Filarial DNA prevalence values in mosquitoes were considered to be significantly dif-
ferent if there was no overlap in the 95% CI values for the two samples. Correlations between
human and mosquito infection parameters were assessed with the Spearman rank test. Graphs
were produced with GraphPad Prism 7 software (La Jolla, CA).
Results
Community survey results
Six areas in 5 districts were resurveyed for W. bancrofti infection parameters between January
2015 and February 2017. LF surveillance periods for sample collections were in Peliyagoda-
watta (Oct., Nov., 2011 and Jan., Feb., 2015); Kalutara North (Sept., Oct., 2011 and Oct., 2015);
Ambalangoda (Nov., Dec., 2011 and March, May 2015); Unawatuna (Nov., Dec., 2011 and
July, Aug., 2015); Weligama (June, Sept., 2012 and Nov., Dec., 2015); Borella (April 2013 and
Oct.,2016 to Feb., 2017). A total of 5350 people from the six sentinel sites participated in the
study. This total included 3123 people in community surveys (ages 10–70, mean age 38 years,
42% males) and 2227 children (age 6–8) in school surveys. Details for enrollment in commu-
nity surveys by sentinel site are provided in Table 1. Few filarial lymphedema cases (34 of
3123, 1.1%) were identified during the survey. Reported bed net use was moderate to high
(range 49% to 70%) in all PHIs studied except Borella.
Survey results are summarized in Table 2. CFA prevalences were lower than 2% in all areas,
but upper confidence limits for CFA were greater than 2% in the two PHI areas in Galle dis-
trict. All CFA tests were negative in two PHIs. CFA prevalence was higher in males than in
females in PHIs with at least one positive card test [13 of 869 (1.5%, 0.8–2.5 CI) vs. 3 of 1211
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(0.2%, 0.1–0.7 CI), P = 0.003]. CFA prevalence was higher in adults (age 18) than in children
(ages 10–17) in the community surveys [15 of 1731 (0.9%, 0.5–1.4 CI) vs. 1 of 349 (0.3%, 0.05–
1.60 CI), P = 0.2]. Ten of 16 persons with positive CFA tests were over the age of 50 (range 54–
69); eight of 10 (80%) CFA positives in this age group were males. Mf prevalences were well
under 1% in all surveyed PHI areas. Three of 16 persons with positive CFA tests in the com-
munity surveys were also Mf positive (range 2–9 Mf count in 60 μl) with one each from Amba-
landgoda, Unawatuna and Weligama.
School survey results
CFA prevalence was low in all PHIs (Table 2), but the upper 95% CI exceeded 2% only in the
Unawatuna PHI (Galle district). Only one of 5 CFA-positive children was Mf-positive (1 mf/
60 μl). Antibody prevalences were higher in the 3 PHI areas in the Southern province (upper
CI close to or higher than 5%) than in the other sentinel sites (Table 2). No child had a positive
antibody test in Borella.
Mosquito monitoring and molecular xenomonitoring
MX results are summarized in Table 3. Filarial DNA was detected in mosquitoes in all of six
PHI areas. However, filarial DNA prevalence exceeded the target (upper CI > 1%) in three






















Colombo Borella a C4 137,423 27,484 127 (0.5) 508 35.3 41.4 24.0 0.4
Gampaha PeliyagodaW b G3 10,560 2112 133 (6.3) 514 35.9 44.2 49.5 2.1
Kalutara Kalutara North KA2 11,728 2032 172 (8.5) 528 39.3 42.6 70.0 1.3
Galle Ambalangoda GL1 13,373 2792 152 (5.4) 523 39.9 40.1 64.4 1.3
Unawatuna GL2 16,636 3660 149 (4.1) 524 38.8 42.5 63.9 0.9
Matara Weligama M2 10,521 2104 169 (8.0) 526 37.0 40.3 67.8 0.6
200,241 40,184 902 (2.2) 3,123 38 42 63 1.1
a Sentinel site C4 is part of the Colombo Municipal Council area.
b Sentinel site G3 is a public health field officer (PHFO) area in a semiurban zone adjacent to Colombo in Gampaha.
c Approximate number of households (HH).
https://doi.org/10.1371/journal.pntd.0006066.t001




Total (%, 95% CI)
CFA Comm Positive/
Total (%, 95% CI)
Mf School Positive/
Total (%, 95% CI)
CFA School Positive/
Total (%, 95% CI)
Ab School Positive/
Total (%, 95% CI)
Colombo Borella C4 0/506 (0, 0–0.7) 0/506 (0, 0–0.7) 0/372 (0, 0–1.0) 0/372 (0, 0–1.0) 0/360 (0, 0–1.0)
Gampaha PeliyagodaW G3 0/512 (0, 0–0.7) 2/512 (0.4, 0.1–1.4) 0/366 (0, 0–1.0) 1/366 (0.3, 0.05–1.5) 2/335 (0.6, 0.1–2.1)
Kalutara Kalutara
North
KA2 0/528 (0, 0–0.7) 0/528 (0, 0–0.7) 0/380 (0, 0–1.0) 0/380 (0, 0–1.0) 9/378 (2.4, 1.3–4.5)
Galle Ambalangoda GL1 1/520 (0.2, 0.3–1.0) 5/520 (1.0, 0.4–2.2) 0/379 (0, 0–1.0) 1/379 (0.3, 0.0–1.5) 8/353 (2.3, 1.1–4.4)
Unawatuna GL2 1/523 (0.2, 0.0–1.0) 8/523 (1.5, 0.8–2.9) 1/359 (0.3, 0.0–1.5) 4/359 (1.1, 0.4–2.8) 14/333 (4.2, 2.5–7.0)
Matara Weligama M2 1/525 (0.2, 0.0–1.0) 1/525 (0.2, 0.0–1.0) 0/371 (0, 0–1.0) 0/371 (0, 0–1.0) 8/367 (2.2, 1.1–4.2)
PHI, Public Health Inspector area; Areas C4 and G3 are PHFO areas. Comm, community; CFA, circulating filarial antigen; Mf, microfilaremia; Ab, IgG4
antibody to Bm14 recombinant filarial antigen by ELISA.
https://doi.org/10.1371/journal.pntd.0006066.t002
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PHIs (Unawatuna and Ambalangoda in Galle district and Weligama in Matara district). Many
trap locations were positive for mosquitoes with filarial DNA in Unawatuna, Ambalangoda
and Weligama (Table 4). The percentages of positive mosquito trap sites in PHIs were not sig-
nificantly correlated with percentages of houses with at least one CFA positive person (Table 4;
Spearman rank correlation, r = 0.5, P = 0.2). Analysis on few data points in 6 areas may have
caused this poor correlation.
Spatial analysis of filarial infections in humans and mosquitoes
The maps in Fig 2A–2D show locations for households surveyed for CFA and mosquito trap-
ping sites in 4 PHIs. Many more positive mosquito trapping locations were identified than
positive households. Positive mosquito trap sites were widely dispersed in three PHIs where
approximately 50% of trap locations yielded mosquitoes with filarial DNA. In contrast, posi-
tive mosquito trap sites in the Kalutara North were concentrated in the southern part of that
PHI.
Table 3. Wuchereria bancrofti DNA prevalence in Culex quinquefasciatus mosquitoes in survey areas.









P value Filarial DNA prevalenceb
in
mosquitoes
Colombo Borella C4 2013 4000 200 26 (13) 0.69 (0.4–1.0)
2016 4000 200 13 (6.5) P = 0.043* 0.34 (0.2–0.6)
Gampaha PeliyagodaW G3 2011 4080 203 17 (8) 0.43 (0.2–0.7)
2015 4000 200 9 (4.5) P = 0.001* 0.23 (0.1–0.4)
Kalutara Kalutara N KA2 2011 4080 204 28 (14) 0.74 (0.4–1.0)
2015 3986 200 10 (5) P = 0.004* 0.26 (0.1–0.4)
Galle Ambalangoda GL1 2011 4000 200 52 (26) 1.40 (1.0–2.0)
2015 3993 200 42 (21) P = 0.28 1.17 (0.8–1.6)
Unawatuna GL2 2011 4000 200 54 (27) 1.50 (1.1–2.0)
2015 4002 200 44 (22) P = 0.29 1.23 (0.8–1.7)
Matara Weligama M2 2012 4080 204 51 (25) 1.40 (1.0–1.9)
2015 4080 204 40 (19.6) P = 0.23 1.09 (0.7–1.5)
a % of total pools with mosquitoes positive for filarial DNA.
b Filarial DNA prevalence (%,maximum likelihood and 95% CI) in mosquito pools were estimated using Poolscreen 2.02 software. P values shown are for
differences relative to % pools positive in 2011, 2013 MX surveys in the same areas. % of pools positive for filarial DNA were significantly lower in Borella,
Peliyagodawatta and Kalutara North*. P values are based on Chi-square analysis
https://doi.org/10.1371/journal.pntd.0006066.t003
Table 4. Filarial infections by household and by trap sites in 6 Public Health Inspector (PHI) areas.
PHI/PHFO Number (%) of CFA positive houses Number (%) positive mosquito trap sites
Borella 0/127 (0) 11/50 (22)
PeliyagodaW 2/133 (1.5) 7/50 (14)
Kalutara North 0/172 (0) 10/50 (20)
Ambalangoda 5/152 (3.3) 24/50 (48)
Unawatuna 7/149 (4.7) 26/50 (52)
Weligama 1/169 (0.6) 25/51 (49)
W. bancrofti infections were detected by antigen (CFA) testing. Filarial DNA was detected by qPCR with
Culex collected in gravid traps.
https://doi.org/10.1371/journal.pntd.0006066.t004
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Community anti-filarial antibody prevalence in two PHI areas with
persistent LF
Community antibody testing was performed in Unawatuna and Weligama PHI areas that had
evidence of persistent W. bancrofti infections and transmission in the baseline surveys. Com-
munity (age10) antibody prevalence was very high in Unawatuna (168/506, 33%, 95% CI
29–37%) and in Weligama (166/501, 33.1%, 95% CI 29–37%), and these values were much
higher in adults (age18) than those in children (Fig 3). Only a small number of people with
positive antibody tests were positive for CFA (6/168 in Unawatuna and 1/166 in Weligama).
Overall anti-filarial antibody prevalence was significantly higher in males than females (42% vs
26%, P = 0.0001, combined results from Unwatuna and Weligama) (Fig 3).
Comparison of W. bancrofti infection parameters over time in 6 PHI
areas
Results from surveys conducted in Peliayagodawatta in 2008, 2011 and 2015 are summarized
in Table 5. W. bancrofti infection parameters spontaneously improved over time in this area,
and most of these changes were statistically significant. In addition, the trend was consistent
over time with greater reductions from baseline 2008 values in 2015 than in 2011.
Fig 2. Distribution of households and mosquito collection sites tested for filariasis in Kalutara North (A), Ambalangoda (B), Unawatuna (C) and
Weligama (D) PHI areas. Blue open circles indicate households (HH) where all tested residents had negative filarial antigen tests; Solid blue circles indicate
houses with at least one resident with a positive filarial antigen test. Trap sites with no mosquito pools positive for filarial DNA are shown with open red circles,
and trap sites with one or more positive mosquito pools are shown with solid red circles. Relatively few CFA positive households were identified, whereas
there were many positive mosquito trap locations (especially in PHIs located in Galle and Matara districts).
https://doi.org/10.1371/journal.pntd.0006066.g002
Fig 3. Summary of prevalence data for community and school antibody (Bm14) positives in 2 PHI areas Unawatuna (Galle
district), Weligama (Matara district) in southern province. Data shown are antibody prevalence (%, 95% CI) by age and gender.
Antibody prevalence in school children within these two communities are shown for 6–8 age for comparison. Antibodies to recombinant
filarial antigen Bm14 were much more frequent in adults than in school age children (ages 10–17), and antibody prevalence was much
higher in adult males than in females. Significance test results (*P values) on antibody prevalence in males are shown for each age group
above the bars.
https://doi.org/10.1371/journal.pntd.0006066.g003
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Longitudinal data on LF infection parameters from all six PHIs are shown in Fig 4. CFA
and MX results improved significantly between 2011 and 2015 in Peliyagodawatta and Kalu-
tara North and between 2013 and 2017 in Borella. There was also a slight downward trend in
some LF parameters in Unawatuna, Ambalangoda and Weligama, but these changes were not
statistically significant even though the government provided one round of MDA with DEC
plus albendazole in Unawatuna and Ambalangoda during this interval. Filarial DNA preva-
lences in mosquitoes were high (MLE > 0.25%, upper CI > 1%) in 2015 in these PHIs.
Negative association of bed net use with filarial infection prevalence
CFA prevalence was significantly lower in Unawatuna and Ambalangoda community partici-
pants (n = 1043, age10) who reported bed net use (0.60% vs 2.42% in non-users, P = 0.01).
There was no association between anti-filarial antibody and bed net use when all ages were
considered in Unawatuna and Weligama, but antibody prevalence in children aged 10–17
were significantly lower in bed net users than in nonusers (8/96, 8.3% vs.12/62, 19.4%,
P = 0.04).
Discussion
This study has provided interesting new data on changes in LF parameters post-MDA. LF
elimination requires reduction of infection parameters to levels that cannot sustainably sup-
port transmission. This does not mean that all measures of LF must be zero, and indeed we
found evidence of low-level persistence of LF in all 6 PHI areas that were restudied in 2015–16.
Breakpoints for LF transmission (where filariasis parameters have been reduced below levels
required for sustained transmission) are poorly defined, and they depend on many factors that
are difficult to measure and may vary widely between and within endemic regions. We have
proposed targets for LF elimination programs [7, 23], and the current study attempted to
Table 5. Summary of Wuchereria bancrofti infection parameters in Peliyagodawatta in 2008, 2011 and 2015.
LF infection markers # tested 2008 Prevalence # tested Prevalence # tested Prevalence
% (95% CI)
2011
% (95% CI) 2015 % (95% CI)
2008 2011 2015
Mf Community 944 0.4 (0.16–1.0) 504 0.4 (0.1–1.4) (NS) 512 0 (0–0.7) (NS)
CFA Community 945 3.8 (2.7–5.2) 504 1.2 (0.5–2.5) 512 0.4 (0.1–1.4)
(P = 0.004)* (P = 0.0001)*
CFA age 6–8 265 1.9 (0.8–4.3) 377 0.3 (0.05–1.5) 366 0.3 (0.05–1.5)
(P = 0.03) (P = 0.03)
Bm14 Ab (6–8) ND ND 350 4.3 (2.6–6.9) 335 0.6 (0.1–1.5)
(P = 0.03)*
Filarial DNA prevalence in mosquitoes. MLEa (% 95% CI) 277 Pools 0.75 (0.52–1.06) 204 Pools 0.43 (0.24–0.71) 200 Pools 0.23 (0.10–0.45)




a MLE: Maximum Likelihood Estimates by PoolScreen in %.
b Percentages of total number of pools with mosquitoes positive for filarial DNA. P values are based on Chi-square. NS, Not significant, ND, Not done. P
values shown in 2011 results column are for differences relative to results of baseline studies performed in 2008. P values shown in 2015 results column are
for differences compared to results of baseline studies in 2008 for antigenemia in community and school, microfilaremia in school children, and filarial DNA
in mosquitoes. P values were calculated for differences in antibody prevalence in school children between 2011 and 2015. P values with “*” symbol were
statistically significant.
https://doi.org/10.1371/journal.pntd.0006066.t005
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Fig 4. Comparison of comprehensive filariasis surveillance data for Kalutara North (KA2),
Ambalangoda (GL1), Unawatuna (GL2), Weligama (M2) and Borella (C4) and Peliyagodawatta (G3)
sentinel sites in Sri Lanka. Data shown are prevalence for LF parameters in community and school children
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“ground truth” these targets. While the time intervals and number of study sites were not suffi-
cient to rigorously prove the validity of the targets, our results suggest that they are in the right
range and also feasible for measurement by national programs. Results from Sri Lanka are
likely to apply to many other LF-endemic areas with transmission by Culex mosquitoes. Long-
term post-MDA surveillance will be needed to verify LF elimination in areas like Sri Lanka
that have highly competent vectors.
As in our prior study, data from 2015–16 again show that MX and antibody testing of
school children are more sensitive than antigen testing of school children for detecting low-
level persistence of LF in post-MDA settings. Results for 3 parameters measured in this study
and in 2011–13 (community CFA, antibody prevalence in school children, and prevalence of
filarial DNA in mosquitoes) support the provisional target values for LF elimination programs
(upper 95% CI values of 2% for community CFA, 5% for antibody in school children, and 1%
for MX), and areas that failed to meet one of the targets often failed to meet the others. Results
from Peliyagodawatta suggest that the community CFA target of 2% in the post-MDA setting
may be too conservative, because the prevalence in that study site declined from 3.8 in 2008 to
0.4% in 2015 without intervention.
One weakness of school-based TAS as currently performed is that signals from focal high
infection areas are often diluted when evaluation units are large. Evaluation Units with popula-
tions of one million or more are commonly employed by LF elimination programs in Asia [1,
4]. The ideal EU size is not known, but reducing the population for EUs to 200,000 or lower
should be more sensitive for detecting persistence or resurgence of LF than the currently rec-
ommended ceiling of 2 million. Large EUs were needed to reduce surveillance costs when the
cost of CFA tests was high. However, recent changes have reduced these costs, and this may
make it feasible to reduce EU size and perform more TAS. A recent study has modeled effects
of EU size and population on sensitivity for detecting ongoing hotspots of transmission [24]. It
is not clear whether this information can be translated into changes in policy or practice that
are feasible for use by national LF elimination programs.
While school-based TAS with a point of care antigen test is a convenient way to sample a
sentinel population for recent infections, this approach is less sensitive than the other parame-
ters that we tested. The strategy of sampling sentinel populations does not work well if the sen-
tinels are at low risk for infection. Antigen data in this study and in our prior study show that
adult males have much higher filarial infection prevalence than other groups in Sri Lanka, and
they represented the bulk (>80%) of the residual reservoir of infection in PHI areas surveyed
in this study. Is this because they have more exposure to infective mosquitoes, higher suscepti-
bility to infection, and lower compliance with MDA, or a combination of these factors? A TAS
that focuses on high-risk adult males to assess the persistent reservoir of infection might be a
more effective tool for post-MDA surveillance than school-based TAS that aims to detect
recent infections.
Antifilarial antibody test results (reflecting both recent and past filarial infections) also
showed age-related increases in prevalence, and antibody prevalence was much higher in
males than females. These results underscore gender and age differences in LF infection and
exposure in Sri Lanka. A post-MDA surveillance study in American Samoa found similar
results with increased infection prevalence in adult males [25]. Our finding of high antibody
prevalence in adults in areas that were close to LF elimination suggest that testing adults with
and prevalence of filarial DNA in mosquitoes (% with 95% confidence intervals). Significance results with P*
values shown for KA2, and G3 are for differences in prevalence for these LF parameters between years in the
same sites.
https://doi.org/10.1371/journal.pntd.0006066.g004
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this antibody test (IgG4 antibodies to recombinant filarial antigen Bm14) has little value as a
post-MDA surveillance tool. Forty-one of 1,700 (2.3%) children tested in 5 PHI areas with one
or more child with a positive antibody test had positive antibody tests, and 6 of these children
had positive antigen tests. These children were born after Sri Lanka’s national MDA program
was completed. Prior studies have shown that persons with positive antifilarial antibody tests
have an increased risk for developing microfilaremia during follow-up [26, 27], so we recom-
mend presumptive treatment for children with positive antibody tests. AFC currently provides
antifilarial treatment to persons with microfilaremia or positive antigen tests according to
WHO guidelines.
The longitudinal results in this study are especially interesting. They suggest that filariasis
parameters in Peliyagodawatta in 2008 and in Kalutara North and Borella in 2011–13 were
already below transmission breakpoints, and LF appears to be on a glide path to elimination in
these areas. On the other hand, results from Unawatuna, Ambalangoda, and Weligama suggest
that transmission is ongoing in these areas and that they will require further intervention. Of
the various parameters measured, the filarial DNA prevelance in mosquitoes (as assessed by
MX) seems to have been the best predictor for LF persistence. Positive MX results in areas
where little or no infection was detected in humans (Borella, Kalutara North, and Peliyagoda-
watta) is intriguing. It is likely that there are infected persons in these communities who were
non-compliant with MDA in the past and also not sampled in our community surveys. Mos-
quitoes do not ask permission when they conduct night blood sampling, and this probably
accounts for the enhanced sensitivity of MX for detecting persistent infections relative to other
modalities.
Results from this study provide useful insights regarding approaches for clearing up LF
transmission hotspots in post-MDA settings like those in southern Sri Lanka. Resumption of
MDA is not an efficient option when human infection prevalence is very low; MDA will not
benefit the vast majority of people who are uninfected, and the program is likely to miss most
persons with persistent infection who have been non-compliant with MDA in the past. The Sri
Lanka AFC provided one round of MDA with DEC plus albendazole in 2014 (prior to this
study), and also provided MDA to selected areas within Galle district in 2015 and 2016. We
believe that instead of focusing on the percentage of the population that can be reached with
MDA (population coverage), programs should focus on how to optimize treatment of infected
persons (worm coverage). Since more than 80% of those with antigenemia in the present study
and approximately 65% of those with antigenemia in the study published in 2014 were adult
males, a “test and treat” program or other approaches that focus on adult males might result in
higher worm treatment coverage than population-based MDA. Population antigen data and
antibody data from children in Unawatuna and Weligama PHIs in Galle and Matara districts
point to a potential protective effect of bed nets for Culex-transmitted LF in Sri Lanka. This
was an unexpected finding, because bed nets are considered to be more important for LF con-
trol in settings with anopheline transmission [28]. Bed nets are popular in Sri Lanka, because
they help to reduce the mosquito nuisance and because they may provide some protection
against dengue virus infection. Additional promotion of bed nets or a focused government
subsidy program for bed nets in selected areas with persistent LF may help to clear remaining
LF hotspots.
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